HENDERSON, NV / ACCESSWIRE / November 19, 2018 / There are several biotech and cannabis companies in the news that could create profit opportunities for investors this week.
Propanc Biopharma, Inc. (PPCB) is one you should look at today. PPCB’s lead product PRP was granted Orphan Drug Designation status by the FDA for the treatment of pancreatic cancer. This qualifies PPCB for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.
PPCB is working towards its first-in-human studies. An upcoming event that could potentially draw some large suitors and investors to the table.
Start your research on PPCB immediately.
Some biotech and pharma stocks to watch include: Propanc Biopharma, Inc. (PPCB), MedMen Enterprises, Inc. (MMNFF), MPX Bioceutical Corporation (OTCQX:MPXEF), CV Sciences, Inc. (OTCQB:CVSI), and OPKO Health, Inc. (NASDAQ:OPK).
Propanc Biopharma, Inc. (PPCB)
Market Cap: $8.49M Share Price: $0.0425
Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.
The Company’s lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries – Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.
MedMen Enterprises, Inc. (MMNFF)
Market Cap: $2.10B Share Price: $4.75
MedMen Enterprises, Inc. (MMNFF), one of the largest marijuana dispensary operators in the United States, plans to raise CAD 120 million ($91 million) after it entered into a letter of engagement with financial services company Canaccord Genuity. MedMen Enterprises said Cannacord will buy on behalf of a group of underwriters a total of 17.65 million units at CAD 6.80 ($5.15) apiece. In addition, the underwritters to the offering have the over-allotment option that includes up to 2.65 million units.
MPX Bioceutical Corporation (MPXEF)
Market Cap: $297.25M Share Price: $0.77
MPX Bioceutical Corporation (MPXEF) announced that the Company will open a new Health for Life dispensary in Nottingham, Maryland which is located at 4741 Ridge Rd, Nottingham, Maryland, 21236. The dispensary is operated by MPX’s indirect wholly-owned subsidiary, S8 Management LLC, through a management agreement with LMS Wellness, Benefit LLC (“LMS”), which provides all management services typically required by a dispensary facility to successfully operate. This is the Company’s third dispensary in Maryland, following the opening of its flagship in Bethdesta, in August 2018 and Baltimore, in October 2018.
CV Sciences, Inc. (CVSI)
Market Cap: $444.47M Share Price: $4.65
CV Sciences Inc. reported Q3/18 earnings November 7, surpassing our expectations, a solid beat. Our prior estimation of CVSI hitting the all-important $50 million sales run rate is confirmed. Top line Y/Y sales growth was over 143%. Our realistic growth expectations indicated Q3/18 revenues would hit $13.3 million; they came in nicely at $13.6. Sequential sales growth hit 10%, exceeding our 8% estimate; this roughly extrapolates to a 45% annual growth rate.
OPKO Health, Inc. (OPK)
Market Cap: $2.08B Share Price: $3.72
Shares of OPKO Health Inc. (OPK) gained more than 16% on Monday after the company posted a third-quarter loss per share of 5 cents on revenue of $249.8 billion, reflecting 1.5% year-over-year growth. The company beat earnings estimates by 2 cents but fell short on revenue expectations by $14.24 million.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting was paid $64,000 cash for one month of service August 25th-Sept. 25th 2018. Regal Consulting was paid $12,000 for two news commentaries in November, and expects to be paid $40,000 for services rendered during the month of October. Regal currently owns 3,638,760 shares of PPCB which it could sell at anytime. All payments were made directly by Propanc Biopharma, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC